Analysis of the Uptake, Metabolism, and Behavioral Effects of Cannabinoids on Zebrafish Larvae.

The Cannabis sativa plant contains numerous phytocannabinoids and terpenes with known or potential biological activity. For decades, plant breeders have been breeding the Cannabis plant to control for a desired ratio of the major cannabinoids. A high-throughput in vivo model to understand the relationship between the chemical composition of different strains and their therapeutic potential then becomes of value. Measuring changes in the behavioral patterns of zebrafish larvae is an established model with which to test the biological activity of neuroactive compounds. However, there is currently little information regarding the uptake kinetics and metabolism of compounds by larvae. In this study, we chose to compare the uptake kinetics and metabolism of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) alone or in combination with their effects on larval behavior. We have shown that both compounds have distinct behavioral patterns and concentration response profiles. Additionally, the uptake kinetics observed for each compound appears to correlate with the change in behavior observed in the behavioral assays. When combinations of THC and CBD were tested there were shifts in both the behavioral activity and the uptake kinetics of each compound compared with when they were tested alone. Finally, the THC/CBD-derived metabolites detected in the larvae are similar to those found in mammalian systems. This study thus provides a model for further testing of additional cannabinoids and potentially plant extracts.

[1]  E. Groce.  The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research , 2018, Journal of Medical Regulation.

[2]  J. McDougall,et al.  Comparison of cannabinoids with known analgesics using a novel high throughput zebrafish larval model of nociception , 2018, Behavioural Brain Research.

[3]  A. Malfitano,et al.  Cannabidiol: State of the art and new challenges for therapeutic applications. , 2017, Pharmacology & therapeutics.

[4]  Su Guo,et al.  Role of the endocannabinoid system in vertebrates: Emphasis on the zebrafish model , 2017, Development, growth & differentiation.

[5]  J. Arnold,et al.  Interactions between cannabidiol and Δ9-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway , 2017, European Neuropsychopharmacology.

[6]  Benjamin J. Whalley,et al.  Molecular Pharmacology of Phytocannabinoids. , 2017, Progress in the chemistry of organic natural products.

[7]  Su Guo,et al.  Identification of environmental stressors and validation of light preference as a measure of anxiety in larval zebrafish , 2016, BMC Neuroscience.

[8]  L. Walker,et al.  Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents , 2016, Pharmacotherapy.

[9]  Michael J. Keiser,et al.  Zebrafish behavioral profiling identifies multi-target antipsychotic-like compounds , 2016, Nature chemical biology.

[10]  R. Dinis-Oliveira.  Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity , 2016, Drug metabolism reviews.

[11]  Christopher S. Krasniak,et al.  Advancing epilepsy treatment through personalized genetic zebrafish models. , 2016, Progress in brain research.

[12]  J. Hallak,et al.  Caffeine protects against memory loss induced by high and non-anxiolytic dose of cannabidiol in adult zebrafish (Danio rerio) , 2015, Pharmacology Biochemistry and Behavior.

[13]  M. Cawthorne,et al.  Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis. , 2015, Journal of hepatology.

[14]  K. Soanes,et al.  Use of the Zebrafish Larvae as a Model to Study Cigarette Smoke Condensate Toxicity , 2014, PloS one.

[15]  B. Brooks,et al.  Similar anxiolytic effects of agonists targeting serotonin 5-HT1A or cannabinoid CB receptors on zebrafish behavior in novel environments. , 2014, Aquatic toxicology.

[16]  Önder Albayram,et al.  Acute administration of THC impairs spatial but not associative memory function in zebrafish , 2014, Psychopharmacology.

[17]  N. Cimino,et al.  Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review , 2014, Drug metabolism reviews.

[18]  A. Stewart,et al.  The behavioral effects of acute Δ9-tetrahydrocannabinol and heroin (diacetylmorphine) exposure in adult zebrafish , 2014, Brain Research.

[19]  Shaukat Ali,et al.  Developmental effects of cannabinoids on zebrafish larvae. , 2013, Zebrafish.

[20]  K. Franson,et al.  The Pharmacologic and Clinical Effects of Medical Cannabis , 2013, Pharmacotherapy.

[21]  W. Silva,et al.  Predator threat stress promotes long lasting anxiety-like behaviors and modulates synaptophysin and CB1 receptors expression in brain areas associated with PTSD symptoms , 2013, Neuroscience Letters.

[22]  F. Guimarães,et al.  Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. , 2012, Journal of psychiatric research.

[23]  H. Baier,et al.  A zebrafish model of glucocorticoid resistance shows serotonergic modulation of the stress response , 2012, Front. Behav. Neurosci..

[24]  K. Soanes,et al.  A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics , 2012, Behavioural Brain Research.

[25]  K. Soanes,et al.  Distinct models of induced hyperactivity in zebrafish larvae , 2012, Brain Research.

[26]  J. Crippa,et al.  Interaction between cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids , 2011, Psychopharmacology.

[27]  I. McGregor,et al.  Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats , 2011, Psychopharmacology.

[28]  C. Maximino,et al.  Pharmacological analysis of zebrafish (Danio rerio) scototaxis , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[29]  F. Guimarães,et al.  Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors , 2010, Behavioural pharmacology.

[30]  Silvio Morato,et al.  Scototaxis as anxiety-like behavior in fish , 2010, Nature Protocols.

[31]  R C MacPhail,et al.  Acute neuroactive drug exposures alter locomotor activity in larval zebrafish. , 2010, Neurotoxicology and teratology.

[32]  O. Carnevali,et al.  A novel role for the endocannabinoid system during zebrafish development , 2009, Molecular and Cellular Endocrinology.

[33]  R C MacPhail,et al.  Locomotion in larval zebrafish: Influence of time of day, lighting and ethanol. , 2009, Neurotoxicology.

[34]  B. Lutz,et al.  The endocannabinoid system: emotion, learning and addiction , 2008, Addiction biology.

[35]  B. Lockwood,et al.  A choice behavior for morphine reveals experience-dependent drug preference and underlying neural substrates in developing larval zebrafish , 2007, Neuroscience.

[36]  R. Rodríguez,et al.  Characterization of cannabinoid-binding sites in zebrafish brain , 2007, Neuroscience Letters.

[37]  U. Strähle,et al.  Distribution of cannabinoid receptor 1 in the CNS of zebrafish , 2006, Neuroscience.

[38]  F. Guimarães,et al.  Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test , 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  F. Guimarães,et al.  Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats , 2006, Behavioural Brain Research.

[40]  H. Maurer,et al.  Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine , 2006, Therapeutic drug monitoring.

[41]  S. File,et al.  Endocannabinoid system and stress and anxiety responses , 2005, Pharmacology Biochemistry and Behavior.

[42]  F. Graeff,et al.  Antianxiety effect of cannabidiol in the elevated plus-maze , 2005, Psychopharmacology.

[43]  L. Bornheim,et al.  Cannabinoid-induced alterations in brain disposition of drugs of abuse. , 2001, Biochemical pharmacology.

[44]  M. Correia,et al.  Purification and characterization of the major hepatic cannabinoid hydroxylase in the mouse: a possible member of the cytochrome P-450IIC subfamily. , 1991, Molecular pharmacology.

[45]  M. Correia,et al.  Selective inactivation of mouse liver cytochrome P-450IIIA by cannabidiol. , 1990, Molecular pharmacology.

[46]  M. Green,et al.  Pharmacological characterization of cannabinoids in the elevated plus maze. , 1990, The Journal of pharmacology and experimental therapeutics.

[47]  A. Zuardi,et al.  Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. , 1984, Archives internationales de pharmacodynamie et de therapie.

[48]  R. J. Thomas,et al.  The toxicologic and teratologic effects of delta-9-tetrahydrocannabinol in the zebrafish embryo. , 1975, Toxicology and applied pharmacology.

[49]  W. O’Shaughnessy.  New Remedy for Tetanus and Other Convulsive Disorders , 1840 .